(2016). Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries. Bmj. http://doi.org/10.1136/bmj.i3903.
(2017). Pioglitazone and risk of mortality in patients with type 2 diabetes: results from a European multidatabase cohort study. BMJ Open Diabetes Res Care. http://doi.org/10.1136/bmjdrc-2016-000364.
(2018). Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom. PLoS One. http://doi.org/10.1371/journal.pone.0204456.
(2018). Pioglitazone and cause-specific risk of mortality in patients with type 2 diabetes: extended analysis from a European multidatabase cohort study. BMJ Open Diabetes Res Care. http://doi.org/10.1136/bmjdrc-2017-000481.
(2021). A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder. Curr Med Res Opin. http://doi.org/10.1080/03007995.2021.1891035.
(2021). Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study. Drug Saf. http://doi.org/10.1007/s40264-021-01095-7.